|
| Status |
Public on Aug 31, 2017 |
| Title |
MUC_00854 |
| Sample type |
genomic |
| |
|
| Channel 1 |
| Source name |
Bone marrow/Blood
|
| Organism |
Homo sapiens |
| Characteristics |
gender: female
tissue: Bone marrow/Blood
diagnosis: Chronic Lymphocytic Leukemia (CLL)
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
DNA was extracted on a Qiacube according to manufacturer's protocol
|
| Label |
Cy5
|
| Label protocol |
labeling was done with SureTag Complete DNA Labeling Kit according to manufacturer's protocol, Cy3 were used for reference sample and Cy5 for the test sample
|
| |
|
| Channel 2 |
| Source name |
Agilent Euro Female
|
| Organism |
Homo sapiens |
| Characteristics |
control type: commercially available normal genomic DNA
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
Catalog number for Agilent male control DNA: #5190-4370. Catalog number for Agilent female control DNA: #5190-4371.
|
| Label |
Cy3
|
| Label protocol |
labeling was done with SureTag Complete DNA Labeling Kit according to manufacturer's protocol, Cy3 were used for reference sample and Cy5 for the test sample
|
| |
|
| |
| Hybridization protocol |
We used SurePrint G3 ISCA CGH+SNP Bundle, 4x180K according to manufacturer's protocol
|
| Scan protocol |
Protocol CytoCGH_0209_4x_Mar14 (Read Only) was used with CytoGenomics v 2.9.1.0 on instrument Agilent G5761A SureScan Dx Microarray Scanner System
|
| Data processing |
Unmodified Raw data provided as separate files from CytoGenomics v2.9.1.0. We have used LogRatio directly extracted from the feature extraction software (Agilent CytoGenomics).
|
| |
|
| Submission date |
Aug 30, 2017 |
| Last update date |
Jan 23, 2018 |
| Contact name |
Torsten Haferlach |
| Organization name |
MLL Munich leukemia laboratory
|
| Street address |
Max-Lebsche-Platz 31
|
| City |
München |
| ZIP/Postal code |
81377 |
| Country |
Germany |
| |
|
| Platform ID |
GPL16237 |
| Series (1) |
| GSE103306 |
Normal karyotype CLL show high rate of SF3B1 mutations and genomic arrays aberrations with impact on time to treatment |
|
